Angiogenic Growth Factors in the treatment of peripheral arterial disease

Current Vascular Pharmacology

Volumn 5, Issue 3, 2007, Pages 195-209

  Mikroulis, Dimitrios ^a,b   Papanas, Nikolaos ^a   Maltezos, Efstratios ^a   Bougioukas, Georgios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Angiogenesis; Growth factors; Peripheral arterial disease; Vascular Endothelial Growth Factor

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; BASIC FIBROBLAST GROWTH FACTOR; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR 1; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOFECTAMINE; LIPOSOME; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NAKED DNA; NERVE GROWTH FACTOR; PLACEBO; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT HYPOXIA INDUCIBLE FACTOR 1; RECOMBINANT PROTEIN; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; ANGIOGENIC PROTEIN; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN A;

ALLERGIC REACTION; ANGIOGENESIS; ANGIOMA; ANGIOPLASTY; ANKLE EDEMA; ARTERY DISEASE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; EDEMA; GENE TRANSFER; HEMODYNAMIC PARAMETERS; HUMAN; HYPOTENSION; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG EDEMA; LEG ISCHEMIA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MUSCLE BLOOD FLOW; MUSCLE FUNCTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEINURIA; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TUMOR; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING; ANIMAL; BLOOD FLOW; DISEASE MODEL; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; TREATMENT OUTCOME;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENIC PROTEINS; ANIMALS; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547598290     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107781024136     Document Type: Review

References (148)

1. Haberl RL, Dembowski K. Atherosclerosis: Common factor in stroke, myocardial infarction and peripheral vascular disease. Eur Heart J Suppl 1999; 1: Suppl A: A41-A44.
2. Dormandy JA, Rutherford RB. Management of Peripheral Arterial Disease, Trans-Atlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 2000; 19:6: suppl A: S1-S250.
3. Ouriel K. Peripheral arterial disease. Lancet 2001; 358:1257-64.
4. Criqui MH. Peripheral vascular disease - epidemiological aspects. Vasc Med 2001; 6: 3-7.
5. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial occlusive disease and atherothrombotic brain infarction in men and women ≥62 years of age. Am J Cardiol 1994; 74: 64-5.
6. Atmer B, Jogestrand T, Laska J, Lund F. Peripheral artery disease in patients with coronary artery disease. Int Angiol 1995; 14:89-93.
7. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-39.
8. Cimminiello C. Peripheral arterial disease as a global vascular risk factor. Haematologica 2001; 86:16-8.
9. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Godman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-5.
10. Fowkes-FGR, Housley E, Cawood EH, Macintyre CA, Ruckley CV, Prescott RJ. Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-92.
11. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 1994; 140: 418-30.
12. Murabito JM, D' Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: A risk profile from the Framingham Heart Study. Circulation 1997; 96: 44-9.
13. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-92.
14. He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg 2006; 44: 33-8.
15. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diGeases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-53.
16. Hiatt WR. Medical treatment of Peripheral Arterial Disease and Claudication. N Engl J Med 2001; 344:1608-1621.
17. Burns P, Lima E, Bradbury AW. What constitutes best medical therapy for peripheral arterial disease? Eur J Vasc Endovasc Surg 2002; 24: 6-12.
18. Lepantalo M, Biancari F, Tukiainen E. Never amputate without consultation of a vascular surgeon. Diabetes Metab Res Rev 2000; 16: Suppl 1: S27-S32.
19. Faries PL, Teodorescu VJ, Morrissey NJ, Hollier LH, Marin ML. The role of surgical revascularization in the management of diabetic foot wounds. Am J Surg 2004; 187: 5A: 34S-37S.
20. Morishita R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004; 95: 1-8.
21. Charney R, Cohem M. The role of the coronary collateral circulation in limiting myocardial ischemia and infarct size. Am Heart J 1993; 126: 937-45.
22. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-63.
23. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-20.
24. Yilmaz MB, Biyikoglu SF, Akin Y, Guray U, Kisacik HL, Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J Obes Relat Metab Disord 2003; 27: 1541-5.
25. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: Basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586-603.
26. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation 2005 112: 1813-24.
27. Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 1992; 116: 435-9.
28. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
29. Folkman J, D' Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87: 1153-5.
30. Tarzami ST, Singh JP. Pharmacological revascularisation in coronary and peripheral vascular disease. Expert Opin Invest Drugs 2004; 13: 1319-26.
31. Folkman J. Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
32. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid. Science 1983; 219: 983-5.
33. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
34. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
35. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Reviews 2004; 25: 581-611.
36. Gerber H, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR is up-regulated by hypoxia. J Biol Chem 1997; 272: 23659-67.
37. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor KDR by hypoxia. Circulation 1996; 94: 1647-54.
38. Wilting J, Birkenhager R, Eichmann A, Kurz H, Martiny-Baron G, Marme D, et al. VEGF induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of the chorioallantoic membrane. Dev Biol 1996; 176: 76-85.
39. Unemori E, Ferrara N, Bauer E, Amento E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557-62.
40. Friedlander M, Brooks P, Shaffer R, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha (v) integrins. Science 1995; 270: 1500-2.
41. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
42. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 263-7.
43. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularisation. Circ Res 1998; 83: 233-40.
44. Morishita R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004; 95: 1-8.
45. Turrini P, Gaetano C, Antonelli A, Capogrossi MC, Aloe L. Nerve growth factor induces angiogenic activity in a mouse model of hindlimb ischaemia. Neurosci Lett 2002; 323: 109-12
46. Emanuelli C, Salis MB, Pinna A, Graiani G, Manni L, Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 2002; 106: 2257-62.
47. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002; 13: 653-61.
48. Shah PB, Losordo DW. Non-viral vectors for gene therapy: Clinical trials in cardiovascular disease. Adv Genet 2005; 54: 339-61.
49. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002; 136: 54-71.
50. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-90.
51. Simons M, Bonow R, Chronos N, Cohen DJ, Giordano FJ, Hammond HK, et al. Clinical trials in coronary angiogenesis: Issues, problems, consensus. Circulation 2000; 102: 73-86.
52. Ho HK, Jang JJ, Kaji S, Spektor G, Fong A, Yang P, et al. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation 2004; 109: 1314-9.
53. Salis Mb, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C. Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hind limb post-ischaemic recovery in mice. Diabetologia 2004; 47: 1055-63.
54. Tang GL, Chang DS, Sarkar R, Wang R, Messina LM. The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis and inflammation in hindlimb ischaemia. J Am Coll Cardiol 2003; 42: 1339-47.
55. Vale PR, Wuensch DI, Rauh GF, Rosenfield K, Schainfeld RM, Isner JM. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty. Circulation 1998; 98: 1-66.
56. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting s, Ferrara N, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischaemia. Circulation 1994; 50: 5 Pt 2: II 228-34.
57. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-70.
58. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 1994; 267: H1263-71.
59. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314-24.
60. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 1995; 91: 2802-9.
61. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649-40.
62. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793-801.
63. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR, Heinsohn HG, et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 1996; 27: 91-8.
64. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J Vasc Surg 1998; 27: 886-94.
65. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227: 628-35.
66. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-90.
67. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998; 27: 699-709.
68. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102: 565-71.
69. Gowdak LH, Poliakova L, Li Z, Grove R, Lakatta EG, Talan M. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J Vasc Surg 2000; 32: 343-52.
70. Neumeister MW, Song YH, Mowlavi A, Suchy H, Mathur A. Effects of liposome-mediated gene transfer of VEGF in ischemic rat gracilis muscle. Microsurgery 2001; 21: 58-62.
71. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 2002; 4: 371-80.
72. Chang DS, Su H, Tang GL, Brevetti LS, Sarkar R, Wang R, et al. Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 2003; 7: 44-51.
73. Springer ML, Hortelano G, Bouley DM, Wong J, Kraft PE, Blau HM. Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. J Gene Med 2000; 2: 279-88.
74. Lu Y, Shansky J, Del Tatto M, Ferland P, Wang X, Vandenburgh H. Recombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis. Circulation 2001; 104: 594-9.
75. Smythe GM, Lai MC, Grounds MD, Rakoczy PE. Adeno-associated virus-mediated vascular and endothelial growth factor gene therapy in skeletal muscle before transplantation promotes revascularization of regenerating muscle. Tissue Eng 2002; 8: 879-91
76. Springer ML, Ozawa CR, Banfi A, Kraft PE, Ip TK, Brazelton TR, et al. Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Mol Ther 2003; 7: 441-9.
77. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical Vascular Endothelial Growth Factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164: 1935-47.
78. Kofidis T, Nolte D, Simon AR, Metzakis A, Balsam L, Robbins R, et al. Restoration of blood flow and evaluation of corresponding angiogenic events by scanning electron microscopy after a single dose of VEGF in a model of peripheral vascular diseage. Angiogenesis 2002; 5: 87-92.
79. Hershey JC, Baskin EP, Corcoran HA, Bett A, Dougherty NM, Gilberto DB, et al. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels. 2003; 18: 142-9.
80. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, et al. Angiogenic gene therapy fpr experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966-73.
81. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-4.
82. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-73.
83. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
84. Rauh G, Gravereaux EC, Pieczek AM, Radley S, Schainfeld RM, Isner JM. Age <50 years and rest pain predict positive clinical outcome after intramuscular gene transfer of phVEGf165 in patients with critical limb ischaemia (Abstract). Circulation 1999; 100: 1-319.
85. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, et al. Vascular Endothelial Growth Factor 165 gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-202.
86. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF (121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753-5.
87. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002; 90: 512-6.
88. Mohler ER 3rd, Rajagopalan S, Olin JW, Trachtenberg JD, Rasmussen H, Pak R, et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: Safety results from a phase I trial. Vasc Med 2003; 8: 9-13.
89. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-33.
90. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-8.
91. Rajagopalan S, Mohler E 3rd, Lederman RJ, Sancedo J, Mendelsohn FO, Olin J, et al. Regional Angiogenesis With Vascular Endothelial Growth Factor trial. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J 2003; 145: 1114-8.
92. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic ctitical leg ischemia. Am J Med 2003; 114: 85-92.
93. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, et al. Lower-extremity edema associated with gene transfer of naked DNA vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-4.
94. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibrolast growth factor. J Vasc Surg 1992; 16: 181-91.
95. Rakue H, Nakajima H, Katoh T, Usui M, Amemiya T, Miyagi M, et al. Low-dose Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor for angiogenesis in canine acute hindlimb insufficiency. Jpn Circ J 1998; 62: 933-9.
96. Baffour R, Garb JL, Kaufman J, Berman J, Rhee SW, Norris MA, et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000; 93: 219-29.
97. Lebherz C, von Degenfeld G, Karl A, Pfosser A, Raake P, Pachmayr F, et al. Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: Effect of venous basic fibroblast growth factor retroinfusion. Endothelium 2003; 10: 257-65.
98. Efthimiadou A, Asimakopoulos B, Nikolettos N, Giatromanolaki A, Sivridis E, Papachristou DN, et al. Angiogenic effect of intramuscular administration of basic and acidic fibroblast growth factor on skeletal muscles and influence of exercise on muscle angiogenesis. Br J Sports Med 2006; 40: 35-9.
99. Efthimiadou A, Nikolettos NK, Lambropoulou M, Papadopoulos N, Kontoleon E. Angiogenic effect of intramuscular administration of basic fibroblast growth factor in atrophied muscles: An experimental study in the rat. Br J Sports Med 2006; 40: 355-8.
100. Hirose K, Fujita M, Marui A, Arai Y, Sakaguchi H, Huang Y, et al. Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. Circ J. 2006; 70: 1190-4.
101. Ohara N, Koyama H, Miyata T, Hamada H, Miyatake SI, Akimoto M, et al. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther. 2001; 8: 837-45.
102. Kondoh K, Koyama H, Miyata T, Takato T, Hamada H, Shigematsu H. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc Res 2004; 61: 132-42.
103. Ishii S, Koyama H, Miyata T, Nishikage S, Hamada H, Miyatake S, et al. Appropriate control of ex vivo gene therapy delivering basic fibroblast growth factor promotes successful and safe development of collateral vessels in rabbit model of hind limb ischemia. J Vasc Surg 2004; 39: 629-38.
104. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, et al. Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial. J Am Coll Cardiol 2000; 36: 1239-44.
105. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 2002; 359: 2053-8.
106. Cooper LT Jr, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, Cooke JP, Hirsch AT. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 235-9.
107. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-6.
108. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
109. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiogenic effect of scatter factor hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis. Circulation. 1998; 97: 381-90.
110. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1379-84.
111. Hayashi S, Morishita R, Nakamura S, Yamamoto K, Moriguchi A, Nagano T, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999; 100 (19 Suppl): II301-8.
112. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-9.
113. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 1996; 28: 409-13.
114. Yoshitomi Y, Kojima S, Umemoto T, Kubo K, Matsumoto Y, Yano M, et al. Serum Hepatocyte Growth Factor in patients with Peripheral Arterial Occlusive Disease. J Clin Endocrinol Metab 1999; 84: 2425-28.
115. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, et al. Safety evaluation of clinical gene therapy using Hepatocyte Growth Factor to treat Peripheral Arterial Disease. Hypertension 2004; 44: 203-9.
116. Yamaguchi T, Sawa Y, Miyamoto Y, Takahashi T, Jau CC, Ahmet I, et al. Therapeutic angiogenesis induced by injecting Hepatocyte Growth Factor in ischemic canine hearts. Surg Today 2005; 35: 855-60.
117. Shimamura M, Sato N, Oshima K, Aoki M, Kurinami H, Waguri S, et al. Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 2004; 109: 424-31.
118. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, et al. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 2001; 37 (2 Part 2): 581-6.
119. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Yamasaki K, et al. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes 2002; 51: 2604-11.
120. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, et al. Therapeutic angiogenesis induced by Human Hepatocyte Growth Factor gene in rat diabetic hind limb ischemia model: Molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-50.
121. Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K, et al. Impairment of collateral formation in Lipoprotein(a) transgenic mice: Therapeutic angiogenesis induced by Human Hepatocyte Growth Factor gene. Circulation 20002; 105: 1491-6.
122. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-71.
123. Koike H, Morishita R, Iguchi S, Aoki M, Matsumoto K, Nakamura T, et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 2003; 17: 779-81.
124. Rajagopalan S, Olin J. Harnessing the response to hypoxia: Use of a constitutively active hypoxia-inducible factor 1α transgene in no-option critical limb ischemia. Circulation 2003; 108: 17: IV-442.
125. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T, et al. Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 2003; 112: 30-41.
126. Rajagopalan S, Olin JW, Young S, Erikson M, Grossman PM, Mendelsohn FO, et al. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 2004; 15: 619-24.
127. Generini S, Tuveri MA, Matucci Cerinic M, Mastinu F, Manni L, Aloe L. Topical application of Nerve Growth Factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes 2004; 112: 542-4.
128. Jiang J, Jiangl N, Gao W, Zhu J, Guo Y, Shen D, et al. Augmentation of revascularization and prevention of plasma leakage by angiopoietin-1 and vascular endothelial growth factor co-transfection in rats with experimental limb ischaemia. Acta Cardiol 2006; 61: 145-53.
129. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92: 9 Suppl: II365-71.
130. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
131. Yang X. Imaging of vascular gene therapy. Radiology 2003; 228: 36-49.
132. Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bouke BN, Cavaliere P, et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled pepetide targeted at alphavbeta3 intergrin after murine hindlimb ischemia. Circulation 2005; 111: 3255-60.
133. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-88.
134. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, et al. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005; 8: 166-63.
135. Jeffers M, Shimkets R, Prayaga S, Boldog F, Yang M, Burgess C, et al. Identification of a novel human Fibroblast Growth Factor and characterization of its role in oncogenesis. Cancer Res 2001; 61: 3131-8.
136. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245-52.
137. Springer ML. A balancing act: Therapeutic approaches for the modulation of angiogenesis. Curr Opin Invest Drugs 2006; 7: 243-50.
138. Aiello LP, Wong J-S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 58: Suppl 77: S113-S119.
139. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, et al. Uncoupling of Vascular Endothelial Growth Factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol 2006; 17: 736-45.
140. Vale PR, Rauh G, Wuensch DI, Pieczek A, Schainfeld RM. Influence of vascular endothelial growth factor on diabetic retinopathy. Circulation 1998; 17: 1-353.
141. Simovic D, Isner JM, Ropper AH, Pieczek A, Weinberg DH. Improvement in chronic ischemic neuropathy after intramuscular phVEGF 165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-8.
142. Isner J, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001; 12: 1593-4.
143. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Arterioscler Thromb Vasc Biol 1997; 17: 2793-800.
144. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, et al. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nepbropathy. J Clin Invest 1995; 96: 2809-19.
145. Yamabe H, Osawa H, Kaizuka M, Tsunoda S, Shirato K, Tateyama F, et al. Platelet-derived growth factor, basic fibroblast growth factor, and interferon-γ increase type IV collagen production in human fetal mesangial cells via a transforming growth factor-β dependent mechanism. Nephrol Dial Transplant 2000; 15: 872-6.
146. Colagiuri S, Borch-Johnsen K, Glumer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48: 1459-63.
147. Yonemitsu Y, Komori K, Sueishi K, Sugimachi K. Gene therapy in vascular surgery comes of age. Surgery 2002; 131(1 Suppl): S261-8.
148. Emanueli C, Madeddu P. Therapeutic angiogenesis: Translating experimental concepts to medically relevant goals. Vascul Pharmacol 2006; 45: 334-9.